Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Misses on EPS, Stock Down 9.29%

This earnings report indicates that Catalyst Pharmaceutical is still facing challenges, as reflected in the negative EPS. The stock's drop of 9.29% suggests that investors are reacting to the lack of revenue information and management's cautious tone. Without updated guidance, uncertainty remains about the company's future performance.